These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 25609739)
1. Maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: who needs what and for how long? de Joode AA; Sanders JS; Rutgers A; Stegeman CA Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i150-8. PubMed ID: 25609739 [TBL] [Abstract][Full Text] [Related]
2. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial. Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368 [TBL] [Abstract][Full Text] [Related]
3. Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management. Plumb LA; Oni L; Marks SD; Tullus K Pediatr Nephrol; 2018 Jan; 33(1):25-39. PubMed ID: 28062909 [TBL] [Abstract][Full Text] [Related]
4. Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial. Tuin J; Stassen PM; Bogdan DI; Broekroelofs J; van Paassen P; Cohen Tervaert JW; Sanders JS; Stegeman CA Clin J Am Soc Nephrol; 2019 Jul; 14(7):1021-1028. PubMed ID: 31253599 [TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. Hiemstra TF; Walsh M; Mahr A; Savage CO; de Groot K; Harper L; Hauser T; Neumann I; Tesar V; Wissing KM; Pagnoux C; Schmitt W; Jayne DR; JAMA; 2010 Dec; 304(21):2381-8. PubMed ID: 21060104 [TBL] [Abstract][Full Text] [Related]
8. The role of rituximab in the treatment of ANCA-associated vasculitides (AAV). Daikeler T; Kistler AD; Martin PY; Vogt B; Huynh-Do U Swiss Med Wkly; 2015; 145():w14103. PubMed ID: 25658140 [TBL] [Abstract][Full Text] [Related]
9. Management of ANCA associated vasculitis. Wallace ZS; Miloslavsky EM BMJ; 2020 Mar; 368():m421. PubMed ID: 32188597 [TBL] [Abstract][Full Text] [Related]
10. [De-escalation of therapy in ANCA-associated vasculitides]. Schinke S; Riemekasten G; Lamprecht P Z Rheumatol; 2017 Feb; 76(1):15-20. PubMed ID: 27933390 [TBL] [Abstract][Full Text] [Related]
11. Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients? Tesar V; Hruskova Z Expert Opin Pharmacother; 2015; 16(11):1683-702. PubMed ID: 26149512 [TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Jones RB; Hiemstra TF; Ballarin J; Blockmans DE; Brogan P; Bruchfeld A; Cid MC; Dahlsveen K; de Zoysa J; Espigol-Frigolé G; Lanyon P; Peh CA; Tesar V; Vaglio A; Walsh M; Walsh D; Walters G; Harper L; Jayne D; Ann Rheum Dis; 2019 Mar; 78(3):399-405. PubMed ID: 30612116 [TBL] [Abstract][Full Text] [Related]
13. Rituximab as maintenance therapy for ANCA associated vasculitis: how, when and why? Alba MA; Flores-Suárez LF Reumatol Clin; 2016; 12(1):39-46. PubMed ID: 26255570 [TBL] [Abstract][Full Text] [Related]
14. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis. Jones RB Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382 [TBL] [Abstract][Full Text] [Related]
18. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH; Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953 [TBL] [Abstract][Full Text] [Related]
19. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Lenert A; Lenert P Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919 [TBL] [Abstract][Full Text] [Related]
20. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis. Timlin H; Lee SM; Manno RL; Seo P; Geetha D Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]